
News|Articles|March 1, 2010
FDA Pipeline preview, March 2010 (CPI-300, Ondansetron, Intravenous acetaminophen, Gabapentin enacarbil, Rifaximin, ENMD-2076, Ap301, CM-AT, Fingolimod, Nilotinib)
Recent FDA action (through March 2010) related to CPI-300, Ondansetron, Intravenous acetaminophen, Gabapentin enacarbil, Rifaximin, ENMD-2076, Ap301, CM-AT, Fingolimod, Nilotinib.
Advertisement
Complete response
Recommendations for approval
Orphan drug designations
Priority review
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
California PBM Law is a Starting Point for Real Transparency
2
WeightWatchers Launches Employer Program for GLP-1 Drugs
3
The Next Breakthrough in Schizophrenia Could be a Digital Therapeutic
4
Professional Pickleball Players Most Likely to Sustain Eye Injury, Least Likely to Wear Eye Protection, Survey Shows | 2025 AAO
5